Q&A with Paul Nelles, Vetter Development Service - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Paul Nelles, Vetter Development Service
Paul Nelles of Vetter Development Service discusses prefilled syringes.


Pharmaceutical Technology
Volume 37, Issue 6, pp. 62
Paul Nelles Vetter

PharmTech: What are the advantages of using prefilled syringes, rather than vials, as the primary packaging earlier in clinical studies as opposed to waiting until later in the development process?

Nelles: As ‘patient and caregiver’ friendly administration systems are in great demand, being able to offer solutions in this field can give a company a distinct advantage. The benefits of using prefilled syringes earlier in the clinical phase may actually improve trial appeal, making it easier to recruit medical clinics for clinical trials that use prefilled syringes instead of using traditional vials. Another clinical advantage of using syringes includes precision single-unit dosing, which better meets the requirements of today’s more complex compounds. In addition, the use of syringes reduces overfilling, thus saving valuable API compared to vials.

PharmTech:  Are there any disadvantages?

Nelles: Cost and time are strong incentives in the world of drug development. Although these aspects can often be more than compensated when looking at the drug-development cycle in total, these are two of the reasons why drug development is traditionally done in vials. Vials are well known and the initial set-up work is simpler and faster. There are definitely cases in which vial development makes the most sense, one being in dose-ranging studies. Vials may also be preferred if the drug is meeting a crucial unmet medical need, in which all resources will be directed toward launching it as quickly as possible in vial only.

PharmTech: What factors need to be considered when using a prefilled syringe as a primary package in clinical studies?

Nelles: When starting syringe development, interactions between the device and a drug substance are often a challenge, for example due to silicon content. If the company plans on differentiating its product via a syringe to create a competitive advantage, however, the challenges associated with drug and device must be considered and rectified anyway. Therefore, it is best to advance the potential risks and challenges associated with the drug-syringe device earlier in the development process, enabling a smoother and quicker market entry later on, with the advanced primary packaging device right from the start.

PharmTech: What impact does this have on the regulatory approval process?

Nelles: Generally speaking, there is no real difference in regulatory requirements between a syringe and a vial. For regulatory approval, you must first demonstrate drug protection, that is, that there are no leaks or leaching. Second, the bioavailability of the drug must be proven. Finally, you must prove stability, with no adverse effects on the drug. This is necessary due to the nature of the syringe, such as the existence of silicone oil, which could impact the drug. As in vial development, syringes are tested for long-term stability, which is six months or longer under GMP conditions.

About the Author
Melanie Sena is the Community Manager for Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here